GeneDx Holdings Corp. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
GeneDx Holdings Corp. (WGS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $100.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-03
- GeneDx Holdings Corp. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- GeneDx Holdings Corp. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $100.00K, a 95.65% decline year-over-year.
- GeneDx Holdings Corp. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $13.80M.
- GeneDx Holdings Corp. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $200.00K.
- GeneDx Holdings Corp. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $16.40M, a 613.04% increase from fiscal 2024.
- GeneDx Holdings Corp. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $2.30M, a 666.67% increase from fiscal 2023.
- GeneDx Holdings Corp. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $300.00K, a 98.34% decline from fiscal 2022.
- GeneDx Holdings Corp. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $18.10M, a 5.85% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $100.00K 10-Q · filed 2026-08-03 | $13.90M derived: sum of 3 quarters · filed 2026-08-03 | $14.10M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $100.00K 10-Q · filed 2026-05-04 | $13.90M derived: sum of 2 quarters · filed 2026-05-04 | $14.10M derived: sum of 3 quarters · filed 2026-05-04 | $14.20M derived: sum of 4 quarters · filed 2026-05-04 |
| 2025-12-31 | $13.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $14.00M derived: sum of 2 quarters · filed 2026-02-23 | $14.10M derived: sum of 3 quarters · filed 2026-02-23 | $16.40M 10-K · filed 2026-02-23 |
| 2025-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $300.00K derived: sum of 2 quarters · filed 2025-10-28 | $2.60M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $2.40M 10-Q · filed 2025-07-29 | ||
| 2025-03-31 | $2.30M 10-Q · filed 2025-04-30 | |||
| 2024-12-31 | $2.30M 10-K · filed 2026-02-23 | |||
| 2023-12-31 | $300.00K 10-K · filed 2026-02-23 | |||
| 2022-12-31 | $18.10M 10-K · filed 2024-02-23 | |||
| 2021-12-31 | $17.10M 10-K · filed 2023-03-16 | |||
| 2020-12-31 | $600.00K 10-K · filed 2023-03-16 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B |